Is oxytocin a therapeutic factor for ischemic heart disease? |
| |
| Institution: | 1. Department of Internal Medicine, Postgraduate Program in Cardiology, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil;2. Department of Nutrition, Harvard School of Public Health, Boston, MA, USA;3. Department of Ophthalmology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil;4. Division of Cardiology, Hospital de Clínicas de Porto Alegre, Centro de Pesquisa Clínica, Porto Alegre, RS, Brazil;5. Department of Social Medicine, Postgraduate Program in Epidemiology, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil;6. Center for Gene Therapy, Hopital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil;7. Department of Applied Informatics, Informatics Institute, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil;1. Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025 China;2. Laboratory of Neurodegenerative Diseases & Key Laboratory of Stem Cell Biology, Institute of Health Science, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine, Shanghai, China;3. Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, China;1. Department of Radiology and Nuclear Medicine, Medical University of Silesia, Katowice, Poland;2. Medical Scientific Society under the Department of Radiology and Nuclear Medicine, Medical University of Silesia, Katowice, Poland;3. School of Technology, Katowice, Poland;4. Department of Neurology, Medical University of Silesia, Katowice, Poland;1. Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China;2. Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China;3. Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China;4. Department of Geriatrics (H.Q.), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China;1. Department of Neurosurgery, Salford Royal NHS Foundation Trust, Stott Lane, Salford, Manchester, M6 8HD, UK;2. Centre for Biostatistics, Institute of Population Health, University of Manchester, Salford Royal NHS Foundation Trust, Stott Lane, Salford, Manchester, M6 8HD, UK;3. Institute of Cardiovascular Sciences, University of Manchester, Salford Royal NHS Foundation Trust, Stott Lane, Salford, Manchester, M6 8HD, UK |
| |
| Abstract: | Ischemic heart disease (IHD) is among the most important and top ranked causes of death in the world, and its preventive and interventional mechanisms are actively being investigated. Preconditioning may still be beneficial in some situations such as IHD. Development of cardioprotective agents to improve myocardial function, to decrease the incidence of arrhythmias, to delay the onset of necrosis, and to limit the total extent of infarction during IHD is of great clinical importance. In order to reduce morbidity, a new treatment modality must be developed, and oxytocin may indeed be one of the candidates. There is increasing experimental evidence indicating that oxytocin may have cardioprotective effects either by decreasing the extent of reperfusion injury or by pharmacologic preconditioning activity. This review shows that in the presence of oxytocin, the cardioprotective effects may be increased to some extent. The presented board of evidence focuses on the valuable effects of oxytocin on myocardial function and candidates it for future clinical studies in the realm of ischemic heart diseases. |
| |
| Keywords: | Oxytocin Cardioprotection Ischemic heart disease Review |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
